RARRES1 and hepatocellular carcinoma: Further, combination treatment with siRARRES1 and lenvatinib led to a higher HCC cell proliferation rate than treatment with lenvatinib alone, indicating that inhibition of RARRES1 decreased HCC cell sensitivity to lenvatinib (Fig. 2G).